RG-13022 is an epidermal growth factor (EGF) inhibitor and PDGF receptor tyrosine kinases.
rg13022 is a egfr tyrosine kinase inhibitor.increased expression of various growth factor receptors including egfr has been observed in human tumours. one therapeutic strategy for overcoming egf autocrine control of tumour growth is to inhibit egfr protein tyrosine kinase.
rg13022 had a dose-dependent, antiproliferative effect on gastric cell lines when grown either in serum-free conditions or in the presence of fcs. western blotting showed that rg13022 treatment led to an inhibition of the egfr phosphorylation in a431 cells and both egfr and c-erbb-2 in mkn45 cells. furthermore, investigation of intracellular signalling pathways suggested that alterations in intracellular signalling were responsible for the actions of rg 13022 in these cells [1].
in rats, rg13022 showed rapid bi-exponential elimination from plasma with a terminal half-life of 50.4 min. rg13022 plasma concentrations were less than 1 μm by 20 min after injection. in addition, rg13022 had no influence on the growth of hn5 tumours when administered chronically, starting either on the tumour inoculation day or after establishment of tumour xenografts. the rapid in-vivo elimination of rg13022 had potential significance to its development, as plasma concentrations fell below that required for in-vitro activity by 20 min after injection [2].
[1] mclaughlin m,brunton v,morrison v,rae a,cooke t,bartlett j. growth inhibition of gastric cancer cell lines by the tyrphostin rg13022 and its effects on intracellular signalling. int j oncol.1996 mar;8(3):589-96.
[2] mcleod hl,brunton vg,eckardt n,lear mj,robins dj,workman p,graham ma. in vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor rg13022. br j cancer.1996 dec;74(11):1714-8.
